Company intelligence / Profile preview

Hemosol Inc.

Mississauga, Ontario, Canadahemosol.com ↗

Ownership: Private
Employees: ~75
Development stage: Phase 2

Overview

Hemosol developed blood substitute products including Hemolink, which underwent Phase II clinical trials. The company faced challenges with safety data and declared insolvency in 2005 after its market value dropped from $600 million in 2000 to $23 million by mid-2003.

Therapeutic areas: HematologyOncologyInfectious Diseases
Modalities: Blood-related protein therapeuticsCell therapeuticsOxygen therapeutics
Industry: Biotech

Drug pipeline

1 asset

Hemoglobin raffimer

Beyond the preview

Go deeper on Hemosol Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hemosol Inc..

Explore the full profile